Crossing the Barrier: What Denali's Hunter Syndrome Approval Reveals About the FDA's Rare Disease Reckoning

There is a wall inside the human body that has defined the limits of neurology for more than a century. The blood-brain barrier, the dense network of cells and tight junctions that separates the brain's circulation from the rest of the body, is one of biology's most elegant defense mechanisms. It keeps pathogens out. It also keeps most drugs out. For children born with Hunter syndrome, a rare genetic disease that progressively destroys the brain as well as the body, that barrier has meant that even the best available treatments could not reach the organ that needed them most.

On March 25, 2026, the FDA approved Avlayah, developed by Denali Therapeutics, as the first biologic specifically engineered to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome. The approval is a genuine scientific milestone. It is also something else: a carefully watched signal about where the FDA stands on rare disease drug development at a moment when that relationship has become unusually fraught.

The Disease and the Problem It Poses

Hunter syndrome, formally known as mucopolysaccharidosis type II or MPS II, is caused by a deficiency of the enzyme iduronate-2-sulfatase. Without it, certain sugar molecules called glycosaminoglycans accumulate in cells throughout the body, damaging the skeleton, heart, liver, and brain. The disease almost exclusively affects boys, with symptoms typically appearing between the ages of two and four. The FDA estimates roughly 500 Americans are living with the condition. For many of them, the neurological progression is the most devastating dimension of the disease, producing cognitive decline, behavioral changes, and loss of developmental milestones that no existing therapy has been able to address.

Takeda's Elaprase, an enzyme replacement therapy approved in 2006, has been the standard of care for nearly two decades. It addresses the systemic manifestations of Hunter syndrome reasonably well. What it cannot do is cross the blood-brain barrier in meaningful quantities. The neurological component of the disease has remained essentially untreated, not because the biology was misunderstood, but because delivering a therapeutic protein to the central nervous system is an engineering problem that has resisted straightforward solutions.

Denali's approach to that problem is the core of what makes Avlayah scientifically interesting. The drug, known chemically as tividenofusp alfa-eknm, is an enzyme replacement therapy fused to a transport vehicle designed to hitch a ride across the blood-brain barrier via the transferrin receptor pathway. The transferrin receptor is expressed on the cells lining the brain's blood vessels and is used by the body to shuttle iron into the central nervous system. Denali's platform exploits that natural transport mechanism to carry the therapeutic enzyme across a barrier that would otherwise exclude it.

What the Approval Is and Is Not

The FDA granted Avlayah accelerated approval, based on a Phase 1/2 study demonstrating that the drug could reduce levels of heparan sulfate in cerebrospinal fluid. Heparan sulfate is one of the glycosaminoglycans that accumulates in Hunter syndrome patients, and its reduction in the CSF is considered a surrogate marker for the drug's activity in the central nervous system. The approval is limited to pediatric patients weighing at least five kilograms who do not yet have advanced neurological impairment, a population where intervention is most likely to preserve function rather than attempt to reverse damage already done.

Accelerated approval means the drug is on the market, but the story is not finished. Denali has a confirmatory trial already underway, designed to demonstrate that the heparan sulfate reduction translates into real clinical benefit for patients. That trial will determine whether the approval converts to a full, traditional approval or whether the FDA eventually requires additional evidence. The agency can demand withdrawal if the confirmatory data do not support the surrogate endpoint's clinical relevance. The Tazverik withdrawal earlier this month, triggered by safety signals in a confirmatory trial, is a reminder that accelerated approval is a conditional status, not a permanent one.

The Regulatory Context That Makes This Approval Significant

The Denali approval did not arrive in a vacuum. It comes after a period of unusual turbulence in the FDA's relationship with rare disease drug developers. Under Commissioner Martin Makary, the agency has simultaneously promoted initiatives designed to accelerate rare disease approvals and delivered a series of surprise rejections that rattled the sector. Regenxbio's gene therapy for Hunter syndrome was rejected earlier this year. UniQure's Huntington's disease gene therapy became the subject of a public dispute between the agency and the company that drew congressional scrutiny. Vinay Prasad, the controversial head of the FDA's Center for Biologics Evaluation and Research, is now stepping down, though the pressure on the agency's rare disease posture has not dissipated with his departure.

Against that backdrop, the Avlayah approval carries a meaning that extends beyond Denali's pipeline. Stifel analyst Paul Matteis described it as a clear step in the right direction for rare disease sponsors, noting that it demonstrates the FDA is still willing to exercise the kind of regulatory flexibility that the accelerated approval pathway was designed to enable. FDA Commissioner Makary appeared to be addressing critics directly in the agency's statement, emphasizing that the FDA can both exercise regulatory flexibility and comply with its legal obligation to approve drugs based on substantial evidence of effectiveness. That framing is not accidental. It is a message to an industry that has been uncertain about what the current FDA will and will not accept.

The Commercial Picture

Avlayah will be priced based on patient weight, reaching approximately $811,000 annually for a patient weighing 30 kilograms. That represents a meaningful premium over Elaprase, which sells for roughly $500,000 per year. The pricing reflects both the novelty of the CNS-targeting mechanism and the small patient population, consistent with the economics of rare disease drug development. Denali also received a priority review voucher as part of the approval, an asset that regularly fetches $150 million or more when sold to other companies seeking to accelerate their own regulatory timelines.

For Denali, the approval is the company's first. The San Francisco-based biotech has been well-funded and scientifically ambitious, but it has also absorbed setbacks, including a failed ALS program. Avlayah represents the first validation of Denali's transport vehicle platform in a human disease, and the implications extend well beyond Hunter syndrome. If the same blood-brain barrier crossing mechanism can be applied to other neurological conditions, the platform's value is considerably larger than a single rare disease indication suggests.

What the Blood-Brain Barrier Crossing Means for Neuroscience

The broader significance of the Avlayah approval is what it says about the tractability of the blood-brain barrier problem. For decades, the inability to deliver large molecules to the central nervous system has constrained the treatment of neurological diseases in ways that have no parallel in other therapeutic areas. Drugs that work beautifully in the periphery fail in the brain not because the biology is wrong but because the delivery is impossible. Denali's transferrin receptor approach is one of several strategies the field has been pursuing to solve that problem, and its first human approval provides a proof of concept that will inform how the broader neuroscience community thinks about CNS drug delivery.

The 500 children and adults in the United States living with Hunter syndrome are not a large commercial market. But the platform that Denali has validated in their disease could, if it continues to perform, become the foundation for treatments in conditions affecting far larger populations. That is the logic that has sustained Denali's valuation through years of development and setbacks. The Avlayah approval does not prove the platform works at scale. It proves it works in humans, which is a different and more important kind of evidence. The next chapter of that story will be written in the confirmatory trial and in whatever indications Denali pursues next.